Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Theriva is a clinical-stage biopharmaceutical company that transitioned its strategic focus to oncology following the 2022 acquisition of VCN Biosciences. The company's primary asset is VCN-01, an oncolytic adenovirus platform designed for intravenous and intravitreal delivery to treat solid tumors, specifically pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma. The company also maintains legacy gastrointestinal assets (SYN-004 and SYN-020) which it is exploring for out-licensing or partnership.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(25.7) million | $(18.3) million |
| Loss Per Share (Basic & Diluted) | $(19.03) | $(28.48) |
| Research & Development Expenses | $12.0 million | $14.3 million |
| General & Administrative Expenses | $7.4 million | $7.1 million |
| Cash and Cash Equivalents (Dec 31, 2024) | $11.6 million | $23.2 million |
| Accumulated Deficit | $(335.0) million | $(309.3) million |
| Net Cash Used in Operating Activities | $(16.9) million | $(19.0) million |
Note: The company has no significant revenue sources and relies on equity financing and grants to fund operations.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately $7.4 million year-over-year, primarily driven by non-cash impairment charges totaling $6.9 million ($5.6 million for Goodwill and $1.3 million for In-Process R&D) and a $700,000 increase in contingent consideration liability.
- Asset Impairments: Due to a sustained decline in stock price, the company recorded a full impairment of Goodwill ($5.6 million) and a partial impairment of In-Process R&D ($1.3 million). Goodwill is now zero on the balance sheet.
- Reduced R&D Spend: R&D expenses decreased by 16% ($2.3 million) due to lower clinical trial costs for the VIRAGE Phase 2 trial and the recognition of a $1.4 million Spanish government R&D tax credit.
- Capital Structure Changes: The company executed a 1-for-25 reverse stock split in August 2024. In September 2024, it completed a public offering raising approximately $2.5 million in gross proceeds and sold approximately 569,000 shares via its At-The-Market (ATM) facility for $3.6 million in net proceeds.
Guidance, Outlook, and Risks
Going Concern Warning
The independent auditor has issued a report containing an explanatory paragraph regarding the company's ability to continue as a going concern. Management states that current cash resources ($11.6 million as of Dec 31, 2024) are sufficient to fund operations only into the third quarter of 2025. The company will require additional capital to complete planned clinical trials and operations beyond this date.
Clinical Outlook
- VCN-01 (PDAC): The Phase 2b VIRAGE trial has completed enrollment of 92 patients. Topline data is anticipated in Q2 2025. The FDA has advised that a stand-alone Phase 3 study is the optimal path forward.
- VCN-01 (Retinoblastoma): Positive topline data was announced from a Phase 1 intravitreal trial. The company received Rare Pediatric Disease Designation from the FDA in July 2024.
- SYN-004: The company does not intend to fund the final cohort of the Phase 1b/2a trial internally without securing a partner or grant funding.
Key Risks
- Liquidity: Failure to raise additional capital could force the company to delay, reduce, or eliminate development programs.
- Regulatory: No products are approved for commercial sale; success depends on clinical trial outcomes and FDA/EMA approvals.
- Listing Status: The company faces risks regarding continued listing on the NYSE American due to stock price volatility and equity requirements, though it recently increased authorized shares.
Investor Verification Checklist
- Cash Runway: Verify the exact date cash reserves will be depleted (management estimates Q3 2025) and the status of any new financing discussions.
- VCN-01 Trial Data: Monitor the release of top-line data from the VIRAGE Phase 2b trial (expected Q2 2025) for efficacy and safety signals.
- Impairment Impact: Confirm that the full write-down of Goodwill and partial write-down of IPR&D are reflected in the balance sheet and that no further impairments are anticipated based on current stock price.
- Partnership Status: Investigate progress on out-licensing or partnering for the SYN-004 and SYN-020 assets, as internal funding for these programs is paused.
- Contingent Consideration: Review the $7.0 million liability for milestone payments to Grifols and the probability assumptions used to value this liability.